Albumin Therapy in Liver Failure
Yes, albumin is appropriate and recommended for specific indications in liver failure, but not as a general resuscitation fluid or nutritional supplement. The evidence strongly supports its use in select clinical scenarios where it reduces mortality and complications 1, 2, 3.
Established Indications with Strong Evidence
Large-Volume Paracentesis
Albumin should be administered at 6-8 g/L of ascites removed when >5L is drained 1. In patients with acute-on-chronic liver failure (ACLF), give this dose regardless of volume removed. Without albumin, 21% of patients develop acute kidney injury (AKI) after large-volume paracentesis, compared to 0% with albumin 1.
Spontaneous Bacterial Peritonitis (SBP)
Give 1.5 g/kg on day 1 and 1.0 g/kg on day 3 1. This regimen reduces:
- AKI from 33% to 10%
- Mortality from 29% to 10%
Patients most likely to benefit have bilirubin >4 mg/dL or baseline creatinine >1.0 mg/dL with BUN >30 mg/dL 1.
Hepatorenal Syndrome
Albumin is recommended as part of standard therapy, typically combined with vasoconstrictors 1, 2, 3.
Acute Liver Failure
Albumin serves dual purposes: maintaining colloid osmotic pressure and binding excess bilirubin 3. The FDA label specifically lists this as an indication.
Controversial or Limited Evidence Areas
Sepsis-Induced Hypotension in Cirrhosis
The evidence here is mixed. One trial showed albumin improved 1-week survival (43.5% vs 38.3%, p=0.03) compared to normal saline 2. However, another trial found higher shock reversal rates but no survival benefit and increased pulmonary complications with 20% albumin versus Plasmalyte 2.
For sepsis with hypotension, albumin may be considered but monitor closely for fluid overload 2.
Long-Term Albumin Administration
The PRECIOSA trial (targeting albumin >3 g/dL in hospitalized patients) showed no benefit and significantly increased pulmonary edema and fluid overload 2. This approach is not recommended.
Critical Pitfalls to Avoid
Volume Overload
This is the most important complication. Recent evidence shows that indiscriminate albumin use, especially targeting specific serum levels, causes pulmonary edema 2. Monitor for:
- Respiratory distress
- Pulmonary edema
- Pleural effusions
Patients with ACLF and those receiving repeated doses are at highest risk 1.
Inappropriate Uses
Do not use albumin for 3:
- Chronic nephrosis (rapidly excreted)
- Chronic cirrhosis as nutritional support
- Protein-losing enteropathies
- General hypoproteinemia without specific indication
Practical Algorithm
Step 1: Identify the specific clinical scenario
- Large-volume paracentesis? → Yes, give albumin
- SBP diagnosis? → Yes, give albumin if bilirubin >4 or creatinine >1.0
- Hepatorenal syndrome? → Yes, give albumin with vasoconstrictors
- Acute liver failure? → Yes, consider albumin
- Sepsis with hypotension? → Maybe, weigh benefits vs fluid overload risk
- General hypoalbuminemia? → No
Step 2: Assess volume status before each dose
- Signs of fluid overload? → Hold or reduce dose
- Adequate hydration? → Proceed
Step 3: Use appropriate formulation
Dosing Summary
| Indication | Dose | Timing |
|---|---|---|
| Large-volume paracentesis | 6-8 g/L removed | During procedure |
| SBP | 1.5 g/kg then 1.0 g/kg | Day 1 and Day 3 |
| Hepatorenal syndrome | Per protocol with vasoconstrictors | Ongoing |
| Acute liver failure | Variable, ~1 g/kg | As needed |
The key distinction is that albumin works through both oncotic effects and non-oncotic properties (anti-inflammatory, antioxidant, binding toxins) in liver failure 1, 4. This explains why it outperforms other colloids like hydroxyethyl starch in head-to-head trials 1.